Results 131 to 140 of about 3,233,658 (249)

Bridging the Racial Disparity Gap in Lipid‐Lowering Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Dinesh K. Kalra
doaj   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

Advanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou, Ruihua Ji, Qinglu Zang, Mingkang Wang, Lingling Zhou, Yingliang Wei, Di Yang, Yue Wu, Hongxu Zhu, Jianrong Wu, Xiaojun Cai, Wenxian Du, Junjie Cheng, An Zeng, Yuehua Li   +14 more
wiley   +1 more source

Magneto‐NIR‐II‐Programmed Cascade Nanozymes Unlocking Blood–Brain Barrier Translocation and Autophagic Resistance in Glioblastoma

Advanced Science, EarlyView.
Magneto‐NIR‐II‐programmed NFSH nanozymes integrate magnetic blood–brain barrier (BBB) translocation, CD44 targeting, multimodal imaging, and cascade catalytic therapy for glioblastoma. Alternating magnetic fields and NIR‐II irradiation amplify ferroptosis, release H2S, suppress autophagic and mitophagic repair, and reshape the immune microenvironment ...
Ruocan Liu, Yundi Wu, Shuai Zhang, Hongjuan Zhao, Jiping Zheng, Shiyang Shao, Jianqiang Chen, Xilong Wu   +7 more
wiley   +1 more source

Performance Estimation and Ex Vivo Validation of Untethered Magnetic Robots in Soft Tissue

Advanced Science, EarlyView.
This study presents an empirical model that quantitatively predicts the step‐out frequency of screw‐type untethered magnetic robots (UMRs) in soft viscoelastic environments, including ex vivo brain tissue. By integrating key parameters into a dimensionless framework, the model enables estimation of robot performance across a range of biological ...
Leendert‐Jan W. Ligtenberg, Thijs J. van der Burg, Stijn Y. Kolkman, Santiago Saavedra Castano, David Fernandez Rivas, Anke Klingner, Roger M. L. M. Lomme, Lucas S. Joziasse, Dorothee Wasserberg, H. Remco Liefers, Doron Ben Ami, Udi Sadeh, Oded Shoseyov, Giulio Dagnino, Pascal Jonkheijm, Jurgen J. Fütterer, Stefano Stramigioli, J. Frank W. Nijsen, Michiel C. Warlé, Islam S. M. Khalil   +19 more
wiley   +1 more source

Senkyunolide I Inhibits mtDNA‐cGAS‐STING Signaling in Macrophages via Targeting VDAC1 Oligomerization to Attenuate Ulcerative Colitis

Advanced Science, EarlyView.
In macrophages, senkyunolide I (SEI) directly targets the K12 residue of VDAC1 to inhibit its stress‐induced oligomerization, a critical upstream event that effectively prevents mitochondrial DNA release and subsequent cGAS‐STING pathway activation.
Zhiming Ye, Yihang Huang, Bohao Han, Lei Zhang, Can Yu, Yang Yang, Bing Liu, Yongping Jian, Zhixiang Xu, Cheng Zeng   +9 more
wiley   +1 more source

Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke

Advanced Science, EarlyView.
ABSTRACT Diabetic stroke is characterized by a hyperglycemic and pro‐inflammatory microenvironment that exacerbates neurovascular dysfunction. However, the blood–brain barrier (BBB) remains a formidable obstacle, restricting the delivery of most therapeutic molecules.
Bixin Shen, Chengxiang Zhang, Junhui Wang, Xichong Zhong, Shihao Chen, Xue Wang, Xiaokun Li, Li Lin   +7 more
wiley   +1 more source

Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy. [PDF]

Cochrane Database Syst Rev
Shokraee K, Bongaerts B, Taneri PE, Escobar Liquitay CM, Olfati S, Zorger AM, Skoetz N, Franco JV.   +7 more
europepmc   +1 more source

Long-Term Mortality Prediction with Pooled Cohort Equations: Implications for Lipid-Lowering Therapy

Background Current guidelines recommend primary prevention statin therapy based on 10-year risk of atherosclerotic cardiovascular disease (ASCVD) assessed by the pooled cohort equations (PCE), while assessing effectiveness through low-density lipoprotein
Shirani, Jamshid, Ma, Zhiyuan, Moran, Lynn N   +2 more
core   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Failing on Both Sides of the Infarct: Lipid-Lowering Therapy and the Delivery Gap. [PDF]

JACC Adv
Milani RV, Lavie CJ.
europepmc   +1 more source